FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies
open_in_new
Read the original article: https://www.cnbc.com/2026/04/30/fda-novo-lilly-glp-1s-compounding.html
info
Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.